Why the study?
Pre-existing devices like AngioVac require invasive extracorporeal circulation support, prompting evaluation of FlowTriever as a less invasive alternative for clot in transit with pulmonary embolism.
Is emergent mechanical thrombectomy using the FlowTriever device feasible for treating right atrial clot and massive pulmonary embolism?
Is emergent mechanical thrombectomy using the FlowTriever device feasible for treating right atrial clot and massive pulmonary embolism?
The FlowTriever device offers a feasible, less invasive alternative to AngioVac for treating right atrial clot in transit associated with massive pulmonary embolism without requiring extracorporeal circulation.
May support less invasive thrombectomy for clot in transit; leaves open comparative trials before practice change.
This case demonstrated a feasible alternative to treat "clot in transit" associated with pulmonary embolism using FlowTriever Inari device. The pre-existing approved AngioVac device requires extracorporeal circulation support and more invasiveness. FlowTriever permits mechanical thrombectomy with versatile approach without additional extracorporeal perfusion setting. Additional studies are required to reach a definitive conclusion.
No takes yet. Share an insight, caveat, or question.
Molano et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: